HepaDisk - A new quality of life questionnaire for HCV patients.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
07 2019
Historique:
received: 28 09 2018
revised: 15 11 2018
accepted: 03 12 2018
pubmed: 22 1 2019
medline: 27 2 2020
entrez: 22 1 2019
Statut: ppublish

Résumé

Since most patients with hepatitis C virus (HCV) infection now receive treatment irrespective of liver disease severity, special attention to patient quality of life (QoL), including psycho-social aspects, is required. No QoL questionnaire is specific for patients with HCV. To develop and validate a short Italian questionnaire (HepaDisk) assessing the QoL of patients affected by HCV with intuitive graphic results that is understandable by patients and physicians. A questionnaire, drafted by a steering committee, underwent a Delphi survey. A multicenter, observational study was conducted to validate the developed HepaDisk versus other tools (CLDQ-I, SF-36, WPAI:HCV), and to evaluate its correlation with disease severity in Italian patients with HCV. The 10-item questionnaire was validated in 214 patients. HepaDisk showed a high correlation with CLDQ overall score and WPAI:HCV activity impairment (Spearman's rank correlation: 0.651 and 0.595, respectively) and a lower correlation with SF-36. Strong internal consistency (Cronbach coefficient: 0.912), good test-retest reliability (Pearson's correlation coefficient: 0.789; 95% CI, 0.714-0.865), and responsiveness to changes among improved patients were demonstrated. HepaDisk is a reliable and user-friendly tool that can monitor disease impact on patient QoL over time, providing a visual representation easily understandable by both patients and physicians.

Sections du résumé

BACKGROUND
Since most patients with hepatitis C virus (HCV) infection now receive treatment irrespective of liver disease severity, special attention to patient quality of life (QoL), including psycho-social aspects, is required. No QoL questionnaire is specific for patients with HCV.
AIMS
To develop and validate a short Italian questionnaire (HepaDisk) assessing the QoL of patients affected by HCV with intuitive graphic results that is understandable by patients and physicians.
METHODS
A questionnaire, drafted by a steering committee, underwent a Delphi survey. A multicenter, observational study was conducted to validate the developed HepaDisk versus other tools (CLDQ-I, SF-36, WPAI:HCV), and to evaluate its correlation with disease severity in Italian patients with HCV.
RESULTS
The 10-item questionnaire was validated in 214 patients. HepaDisk showed a high correlation with CLDQ overall score and WPAI:HCV activity impairment (Spearman's rank correlation: 0.651 and 0.595, respectively) and a lower correlation with SF-36. Strong internal consistency (Cronbach coefficient: 0.912), good test-retest reliability (Pearson's correlation coefficient: 0.789; 95% CI, 0.714-0.865), and responsiveness to changes among improved patients were demonstrated.
CONCLUSION
HepaDisk is a reliable and user-friendly tool that can monitor disease impact on patient QoL over time, providing a visual representation easily understandable by both patients and physicians.

Identifiants

pubmed: 30661988
pii: S1590-8658(18)31304-5
doi: 10.1016/j.dld.2018.12.009
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1008-1015

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Stefano Fagiuoli (S)

Gastroenterology, Hepatology and Transplantation Unit, ASST-Papa Giovanni XXIII, Bergamo, Italy.

Nicola Caporaso (N)

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Filomena Morisco (F)

Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Fabio Buelli (F)

Medical Department, AbbVie srl, Rome, Italy.

Giuliana Gualberti (G)

Medical Department, AbbVie srl, Rome, Italy. Electronic address: giuliana.gualberti@abbvie.com.

Valeria Saragaglia (V)

Medical Department, AbbVie srl, Rome, Italy.

Luchino Chessa (L)

Liver Unit, University Hospital, Monserrato, Cagliari, Italy.

Giampaolo Corti (G)

University Hospital Careggi, University of Florence, Florence, Italy.

Ivana Maida (I)

University Hospital of Sassari, Sassari, Italy.

Claudio M Mastroianni (CM)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Mario Pirisi (M)

Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Francesco P Russo (FP)

Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital Padua, Padua, Italy.

Francesca Farina (F)

Infectious Diseases Unit, "ULSS 2", Treviso, Italy.

Lydia Giannitrapani (L)

Internal Medicine Unit, University Hospital Policlinico P. Giaccone, Palermo, Italy.

Pierluigi Toniutto (P)

Hepatology and Liver Transplantation Unit, Department of Medical Area (DAME), University of Udine, Udine, Italy.

Pierluigi Tarquini (P)

Infectious Diseases Unit, Hospital "G. Mazzini", Teramo, Italy.

Paolo Tundo (P)

Infectious Diseases Unit, Presidio Ospedaliero S. Caterina Novella Galatina, Galatina (LE), Italy.

Jacopo Vecchiet (J)

Infectious Diseases Unit, Clinical Hospital SS Annunziata, Chieti, Italy.

Maria Vinci (M)

Niguarda Great Metropolitan Hospital, Milan, Italy.

Gloria Taliani (G)

Cronic Infectious Diseases Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH